Literature DB >> 19462341

The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.

Daniela Eser1, Caroline Nothdurfter, Cornelius Schüle, Julia Damm, Yvonne Steng, Hans-Jürgen Möller, Rainer Rupprecht, Thomas Baghai.   

Abstract

BACKGROUND: Electroconvulsive therapy (ECT) is still considered the most effective biological treatment strategy in psychiatric disorders. However, the clinical efficacy of ECT may be affected by stimulus variables and the concomitant use of psychopharmacological medication. Furthermore, most anaesthetics have anticonvulsant properties and therefore might additionally influence the efficacy of ECT.
METHOD: In order to explore whether different anaesthetics might alter the effectiveness or safety of ECT we retrospectively analyzed 5482 ECT treatments in 455 patients. Anaesthetics were chosen according to clinical reasons and comprised thiopental, methohexital, propofol and etomidate.
RESULTS: Seizure duration was significantly affected by the anaesthetic medication with longest seizure activity during thiopental anaesthesia. In addition, postictal suppression, a further prospective parameter of ECT effectiveness, was significantly higher during propofol and thiopental anaesthesia. The clinical effectiveness was significantly better during propofol and thiopental anaesthesia. In contrast, the overall safety did not differ between the anaesthetic groups.
CONCLUSION: Our study supports the hypothesis that inducting anaesthetic agents have a different impact on seizure duration, ictal and postictal electrophysiological indices and clinical efficacy of ECT. Compared to thiopental, which has been established as a standard anaesthetic during ECT, also the modern anaesthetic propofol is a suitable inducting agent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19462341     DOI: 10.1080/15622970902960897

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  8 in total

1.  Patients' physical response to thiopental and alternative anesthetic agents in the setting of electroconvulsive therapy.

Authors:  Kayleigh Gordon; Donna M M Woloschuk; Ashley N Walus
Journal:  Can J Hosp Pharm       Date:  2014-11

2.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

3.  Management of poor postictal suppression during electroconvulsive therapy with propofol anesthesia: a report of two cases.

Authors:  Jonathan T Stewart
Journal:  J Anesth       Date:  2012-07-24       Impact factor: 2.078

4.  Propofol protects against impairment of learning-memory and imbalance of hippocampal Glu/GABA induced by electroconvulsive shock in depressed rats.

Authors:  Jie Luo; Su Min; Ke Wei; Ping Li; Jun Dong; Yong-Feng Liu
Journal:  J Anesth       Date:  2011-07-19       Impact factor: 2.078

5.  Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study.

Authors:  Carolin Hoyer; Laura Kranaster; Christoph Janke; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

6.  The influence of anaesthetic choice on seizure duration of electroconvulsive therapy; etomidate versus methohexital.

Authors:  Laila Chomrikh; Mustafa Ahmadi; T Martijn Kuijper; Joris J B van der Vlugt; Seppe J H A Koopman
Journal:  BMC Anesthesiol       Date:  2022-07-05       Impact factor: 2.376

7.  Comparison of anesthetics in electroconvulsive therapy: an effective treatment with the use of propofol, etomidate, and thiopental.

Authors:  Guy Sender Zahavi; Pinhas Dannon
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-20       Impact factor: 2.570

8.  Medication management during electroconvulsant therapy.

Authors:  Monica Zolezzi
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.